Mitsubishi UFJ Asset Management Co. Ltd. Increases Holdings in Pfizer Inc. $PFE

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Pfizer Inc. (NYSE:PFE) by 4.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,396,271 shares of the biopharmaceutical company’s stock after purchasing an additional 464,449 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.20% of Pfizer worth $290,377,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer in the third quarter valued at $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the 2nd quarter valued at about $30,000. True Wealth Design LLC increased its holdings in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Pfizer during the second quarter worth about $32,000. Finally, Evelyn Partners Asset Management Ltd purchased a new stake in shares of Pfizer in the second quarter valued at about $33,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA gives full approval to Pfizer’s BRAFTOVI combination for first‑line metastatic colorectal cancer — a clear commercial positive for oncology revenue and uptake. Read More.
• Positive Sentiment: Pfizer secures China commercialization partner (Sciwind) for a next‑generation weight‑loss GLP‑1 candidate, expanding market access in a high‑growth obesity/diabetes segment and unlocking up to ~$495M in deal value. Read More.
• Positive Sentiment: Dividend narratives strengthen investor interest — coverage pieces highlight Pfizer’s high yield and management’s commitment to the payout, supporting income‑oriented demand. Read More.
• Neutral Sentiment: Pfizer updated clinical activity in China (pneumococcal vaccine Phase 1) — constructive for long‑term vaccine opportunity but near‑term commercial impact is unclear. Read More.
• Neutral Sentiment: Industry pieces and comparisons (Novo Nordisk, J&J, large‑cap pharma commentary) are placing Pfizer within a broader sector narrative about defensiveness and AI‑driven R&D — useful context but not company‑specific catalysts. Read More.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform/“$25” target and warned of an expected $15B–$20B structural revenue decline through 2030 — a significant bearish forecast that pressures valuation expectations. Read More.
• Negative Sentiment: Zacks moved Pfizer from “strong sell” to “hold,” improving its tone but reflecting continued analyst caution; RBC/other outlets are still negative which keeps analyst sentiment mixed. Read More.
• Negative Sentiment: Pfizer terminated an early‑stage ulcerative colitis study (Phase 1b), representing a pipeline setback and incremental downside risk to future growth prospects. Read More.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on PFE shares. TD Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. HSBC reissued a “buy” rating and issued a $29.00 price target on shares of Pfizer in a report on Wednesday, December 10th. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $27.70.

Pfizer Price Performance

PFE opened at $27.11 on Thursday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The company’s 50 day simple moving average is $26.04 and its 200 day simple moving average is $25.37. The stock has a market capitalization of $154.11 billion, a PE ratio of 19.93 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.